<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030012</url>
  </required_header>
  <id_info>
    <org_study_id>RP-NIOA2019001Reg</org_study_id>
    <nct_id>NCT05030012</nct_id>
  </id_info>
  <brief_title>Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants</brief_title>
  <acronym>MODERATION Neo</acronym>
  <official_title>Maintaining Optimal Delivery Using Automatic Titration of Oxygen in Preterm Infants Receiving High Velocity Nasal Insufflation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vapotherm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vapotherm, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxygen treatment is common in management of preterm babies requiring intensive care. Delivery&#xD;
      of too much or too little oxygen increase the risk of damage to eyes and lungs, and&#xD;
      contributes to death and disability. Oxygen control in preterm infants requires frequent&#xD;
      adjustments in the amount of oxygen delivered to the baby. This is generally performed&#xD;
      manually by a clinician attending the baby, and generally directed to maintaining a specific&#xD;
      range of blood oxygen saturation. The manual control often results in only half of the time&#xD;
      in the specified range, with the baby experiencing high and low blood oxygen saturations.&#xD;
&#xD;
      The technology being studied is designed to assist the clinician in maintaining blood oxygen&#xD;
      saturation within target range by measuring oxygen saturation and automatically adjusting the&#xD;
      amount of oxygen delivered for babies receiving high velocity nasal insufflation (an advanced&#xD;
      form of high flow oxygen therapy). The proposed study will evaluate the efficacy and safety&#xD;
      of the automatic control of oxygen by the new technology, as compared to manual control,&#xD;
      among babies receiving high velocity therapy in a neonatal intensive care unit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: Supplemental oxygen is commonly administered to babies in neonatal&#xD;
      intensive care units. The goal of oxygen therapy is to maintain normal oxygenation while&#xD;
      minimizing hypoxemia and hypoxemia. Preterm infants are particularly vulnerable to oxygen&#xD;
      toxicity and oxidative stress leading to retinopathy of prematurity (ROP), bronchopulmonary&#xD;
      dysplasia (BPD), and periventricular leukomalacia (PVL). It's also well known that preterm&#xD;
      infants experience hypoxic events exposing the baby to low oxygen levels. These hypoxic&#xD;
      events vary as the infant matures, but exposure to prolonged and frequent episodes of&#xD;
      hypoxemia is associated with increased morbidity and mortality. The delivery of oxygen is&#xD;
      generally controlled by a clinician, and the control decisions are generally made using a&#xD;
      non-invasive measure of blood oxygen saturation called pulse oximetry (SpO2) and is a&#xD;
      standard of care in the neonatal intensive care unit. The most frequent item adjusted by&#xD;
      clinicians to maintain SpO2 within specific target ranges is the fraction of the inspired&#xD;
      oxygen (FiO2).&#xD;
&#xD;
      In a recent study by Reynolds, et al., caregiver manual control of oxygen delivered to NICU&#xD;
      babies receiving high velocity therapy resulted in only 49% of the total 24-hour study period&#xD;
      with the babies within the target SpO2 range (90-95%). by the caregiver based on the&#xD;
      monitored oxygen saturation. Similar to the Reynolds findings, Hagadorn et al., conducted a&#xD;
      study in 14 centers and showed that preterm infants under 28 weeks' gestation receiving&#xD;
      oxygen spent on average only 48% of the time with SpO2 within the prescribed target range,&#xD;
      about 36% of the time above and 16% of the time with SpO2 below the target range.&#xD;
&#xD;
      Preterm infants have frequent fluctuations in SpO2 due to their cardio-respiratory&#xD;
      instability requiring frequent adjustments of FiO2 . Consequently, these particularly&#xD;
      vulnerable infants spend significant time with SpO2 outside the optimal target range and are&#xD;
      often exposed to extremes of hypoxemia and hyperoxaemia. The automatic oxygen control system&#xD;
      continuously monitors the oxygen saturation and adjusts the oxygen delivery to maintain&#xD;
      oxygen saturation within the target range. The efficacy of this mode of oxygen control was&#xD;
      demonstrated by Reynolds, et al. in 2018 from two centers in the United Kingdom. Automated&#xD;
      control of FiO2 can significantly improve compliance of oxygen saturation targeting and may&#xD;
      significantly reduces exposure to hypoxemia as well as hyperoxaemia. The high velocity nasal&#xD;
      insufflation therapy is a common mode of non-invasive respiratory support in preterm infants.&#xD;
&#xD;
      Unlike prior studies, this study will include a set of hypothesis-driven safety endpoints&#xD;
      (proportion of time above or below target range), stratification by body mass at enrolment,&#xD;
      and skin pigmentation phenotype. The objective of this randomized control trial is to&#xD;
      evaluate the efficacy of the controller (Vapotherm Oxygen Assist Module [OAM]) in maintaining&#xD;
      the SpO2 within target range for premature infants receiving high velocity therapy and&#xD;
      presenting with a labile FiO2 requirement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study will be a prospective, multi-center, randomized, crossover trial evaluating automated oxygen titration versus manual titration in maintaining oxygen saturation levels in preterm infants requiring noninvasive ventilatory support via high velocity nasal insufflation (HVNI).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This study is unblinded, as there is a distinct difference in modality control between automated and manual modes. Clinical staff are instructed to perform FiO2 adjustments as required, regardless of the study arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Objective - Proportion of Time Outside of SpO2 Target Range</measure>
    <time_frame>Through study completion, two consecutive 24-hour periods</time_frame>
    <description>Percentage of time spent outside target oxygen saturation range, measured by pulse oximetry (SpO2). A lower value indicates a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Performance Objective - Proportion of Time Within SpO2 Target Range</measure>
    <time_frame>Through study completion, two consecutive 24-hour periods</time_frame>
    <description>Percentage of time spent within target oxygen saturation range, measured by pulse oximetry (SpO2). A higher value indicates a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Objective 1 - Proportion of Time Within SpO2 Target Range (Weight Groups)</measure>
    <time_frame>Through study completion, two consecutive 24-hour periods</time_frame>
    <description>Percentage of time spent within target oxygen saturation range across two weight groups (1000-1500g, 1500-2500g), measured by pulse oximetry (SpO2). A higher value indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Performance Objective 2 - Proportion of Time Within SpO2 Target Range (Skin Pigmentation)</measure>
    <time_frame>Through study completion, two consecutive 24-hour periods</time_frame>
    <description>Percentage of time spent within target oxygen saturation range across two skin pigmentation groups (light, dark), measured by pulse oximetry (SpO2). A higher value indicates a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Infant, Premature</condition>
  <condition>Neonatal Respiratory Distress</condition>
  <condition>Oxygen Saturation</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Automated Control (OAM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be adjusted by the Oxygen Assist Module (OAM) to keep the infants pulse oxygen saturation within a target range (90-95%). Clinical staff will have the ability to override FiO2 levels when required, and instructed to do so.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual Control (Manual)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, FiO2 levels delivered via high-velocity nasal insufflation therapy (Vapotherm Precision Flow) will be manually adjusted by clinical staff to keep infants' oxygen saturation between 90-95%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Automated Control</intervention_name>
    <description>The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.</description>
    <arm_group_label>Automated Control (OAM)</arm_group_label>
    <other_name>Oxygen Assist Module (OAM)</other_name>
    <other_name>Vapotherm OAM + Vapotherm Precision Flow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Manual Control</intervention_name>
    <description>The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.</description>
    <arm_group_label>Manual Control (Manual)</arm_group_label>
    <other_name>Vapotherm Precision Flow</other_name>
    <other_name>Treatment as Usual (TAU)</other_name>
    <other_name>Standard of Care (SOC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preterm infants being treated with high velocity nasal insufflation therapy&#xD;
&#xD;
          -  Patients that clinically require SpO2 maintenance within the target range of 90-95%&#xD;
&#xD;
          -  A need for supplemental oxygen as demonstrated by a required FiO2 &gt; 0.25 at enrollment&#xD;
&#xD;
          -  Requiring a flow rate of greater than 2 Lâ€¢min-1 such that the assumed inspired oxygen&#xD;
             fraction matched delivered oxygen fraction (definition of HVNI).&#xD;
&#xD;
          -  A minimum of 12 manual FiO2 adjustments in the 24hr period prior to trial enrollment.&#xD;
&#xD;
          -  Parents willing/able to complete informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current patient weight of &lt;1000g or &gt;2500g at time of study&#xD;
&#xD;
          -  Major congenital abnormalities&#xD;
&#xD;
          -  Hemodynamic instability, defined as being outside of a normotensive range based on an&#xD;
             infant's individual characteristics by clinician&#xD;
&#xD;
          -  Persistent unresolved apnea defined as: requiring 6 stimulations or more per 6 hours&#xD;
&#xD;
          -  Seizures&#xD;
&#xD;
          -  Ongoing sepsis&#xD;
&#xD;
          -  Meningitis&#xD;
&#xD;
          -  Clinician's concern regarding stability of the infant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billie L Short, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khodayar Rais-Bahrami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert J DiGeronimo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert DiBlasi, RRT-NPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley A Yoder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George C Dungan, II, MPhil (Med)</last_name>
    <phone>2673473305</phone>
    <email>gdungan@vtherm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonithas I Volakis, MS, PhD</last_name>
    <phone>7347173312</phone>
    <email>lvolakis@vtherm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's National Hospital &amp; Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley A Yoder, MD</last_name>
      <phone>801-581-7052</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reynolds PR, Miller TL, Volakis LI, Holland N, Dungan GC, Roehr CC, Ives K. Randomised cross-over study of automated oxygen control for preterm infants receiving nasal high flow. Arch Dis Child Fetal Neonatal Ed. 2019 Jul;104(4):F366-F371. doi: 10.1136/archdischild-2018-315342. Epub 2018 Nov 21.</citation>
    <PMID>30464005</PMID>
  </reference>
  <reference>
    <citation>Hagadorn JI, Furey AM, Nghiem TH, Schmid CH, Phelps DL, Pillers DA, Cole CH; AVIOx Study Group. Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks' gestation: the AVIOx study. Pediatrics. 2006 Oct;118(4):1574-82.</citation>
    <PMID>17015549</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Velocity Nasal Insufflation (HVNI)</keyword>
  <keyword>Preterm Infants</keyword>
  <keyword>Noninvasive Ventilatory Support</keyword>
  <keyword>Automatic Oxygen Titration</keyword>
  <keyword>Closed Loop Oxygen Control</keyword>
  <keyword>High Flow Nasal Cannula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

